ACTR-18. PHASE II TRIAL OF TEMOZOLOMIDE AND TRC 102, BASE EXCISION REPAIR INHIBITOR, IN BEVACIZUMAB NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE

BACKGROUND: Temozolomide forms O(6)-methylguanine (O(6)mG), 7-methylguanine (N(7)mG), and 3- methyladenine (N(3)mA) DNA adducts. The O(6)mG DNA adduct is repaired by MGMT. N(7)mG and N(3)mA DNA adducts are removed by the base excision repair (BER) pathway. TRC-102 is a BER inhibitor that binds to th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Ahluwalia, Manmeet, Drappatz, Jan, Ye, Xiaobu, Walbert, Tobias, Holdhoff, Matthias, Lesser, Glenn, Cloughesy, Tim, Peereboom, David, Burt Nabors, L, Wen, Patrick, Grossman, Stuart, Rogers, Lisa
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216166/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.052
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados